IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

Front Immunol. 2024 Apr 15:15:1331217. doi: 10.3389/fimmu.2024.1331217. eCollection 2024.

Abstract

Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases. We propose studies to advance IL-23 biology and unravel differences in response to anti-IL-23 therapy. Experimental evidence generated from these investigations could establish a novel molecular ontology centered around IL-23-driven diseases, improve upon current approaches to treating IMIDs with IL-23 inhibition, and ultimately facilitate optimal identification of patients and, thereby, outcomes.

Keywords: IL-23; cytokine; immune-mediated inflammatory diseases; inflammatory bowel disease; psoriasis; psoriatic arthritis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Arthritis, Psoriatic / drug therapy
  • Arthritis, Psoriatic / immunology
  • Humans
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / immunology
  • Inflammatory Bowel Diseases / therapy
  • Interleukin-23* / antagonists & inhibitors
  • Interleukin-23* / immunology
  • Interleukin-23* / metabolism
  • Psoriasis / drug therapy
  • Psoriasis / immunology
  • Signal Transduction

Substances

  • Interleukin-23

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors declare that this study received funding from Janssen Global Services, LLC. The funder had the following involvement in the study: preparation of the article.